{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:06:18Z","timestamp":1784577978587,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jad.2026.122106","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:47:14Z","timestamp":1780933634000},"page":"122106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance"],"prefix":"10.1016","volume":"412","author":[{"given":"Dian-Jeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4136-1251","authenticated-orcid":false,"given":"Tien-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chang","family":"Changchien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ya","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.122106_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cpr.2005.11.005","article-title":"Relapse to alcohol and drug use among individuals diagnosed with co-occurring mental health and substance use disorders: a review","volume":"26","author":"Bradizza","year":"2006","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.jad.2026.122106_bb0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/add.14596","article-title":"Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study","volume":"114","author":"Brenner","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.jad.2026.122106_bb0015","doi-asserted-by":"crossref","DOI":"10.1007\/s43440-026-00843-9","article-title":"Ketamine for comorbid treatment-resistant depression and substance use disorders: balancing risks and opportunities","author":"Brody","year":"2026","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jad.2026.122106_bb0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1176\/appi.ajp.20240859","article-title":"Treating depression with repetitive transcranial magnetic stimulation: a clinician\u2019s guide","volume":"182","author":"Chen","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/gps.70111","article-title":"Real-world effectiveness and tolerability of prolonged intermittent theta burst stimulation in older adults with treatment-resistant depression","volume":"40","author":"Cheng","year":"2025","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122106_bb0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/1570159X22666240827165327","article-title":"Major depression in comorbidity with substance use disorders: patients\u2019 features and clinical-neurobiological rationale of antidepressant treatments","volume":"23","author":"De Filippis","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jad.2026.122106_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.12788\/acp.0094","article-title":"Repetitive transcranial magnetic stimulation (rTMS) is associated with increased abstinence in substance use disorders and comorbid depression","volume":"35","author":"Foad","year":"2023","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/02698811241254834","article-title":"Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems","volume":"38","author":"Gent","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122106_bb0055","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1038\/s41380-021-01167-1","article-title":"Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al","volume":"26","author":"Heifets","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0060","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2215-0366(15)00207-2","article-title":"Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study","volume":"2","author":"Hjorthoj","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115979","article-title":"Response trajectory to left dorsolateral prefrontal rTMS in major depressive disorder: a systematic review and meta-analysis: trajectory of rTMS","volume":"338","author":"Hsu","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.122106_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.104082","article-title":"Real-world outcome of rTMS treatment for depression within the Japanese public health insurance system: registry data from Kansai TMS network","volume":"97","author":"Imazu","year":"2024","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2026.122106_bb0075","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/13696998.2023.2188845","article-title":"Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans","volume":"26","author":"Joshi","year":"2023","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jad.2026.122106_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.jad.2026.122106_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2026.122106_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","article-title":"Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms","volume":"49","author":"Krystal","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.122106_bb0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jad.2024.07.128","article-title":"A replication study using the World Health Organization pharmacovigilance database (VigiBase(R)) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists","volume":"363","author":"Kwan","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122106_bb0100","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: a scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122106_bb0105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euroneuro.2022.02.004","article-title":"Ketamine and esketamine for crisis management in patients with depression: why, whom, and how?","volume":"57","author":"Lengvenyte","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122106_bb0110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1037\/a0019943","article-title":"Clinical outcomes of an integrated treatment for depression and substance use disorders","volume":"24","author":"Lydecker","year":"2010","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.jad.2026.122106_bb0115","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122106_bb0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41386-023-01776-0","article-title":"A systematic review and meta-analysis of neuromodulation therapies for substance use disorders","volume":"49","author":"Mehta","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2026.122106_bb0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2026.122106_bb0140","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/add.13788","volume":"112","author":"Ostergaard","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jad.2026.122106_bb0145","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1093\/pubmed\/fdv148","article-title":"Substance use disorder and risk of suicidal ideation, suicide attempt and suicide death: a meta-analysis","volume":"38","author":"Poorolajal","year":"2016","journal-title":"J. Public Health (Oxf.)"},{"key":"10.1016\/j.jad.2026.122106_bb0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jad.2014.11.015","article-title":"Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): a 6-month, open label, follow-up study","volume":"174","author":"Rapinesi","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122106_bb0155","first-page":"1","article-title":"Safety and efficacy of ketamine for the treatment of patients with alcohol use disorder: a systematic review","author":"Rathore","year":"2025","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.jad.2026.122106_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241310685","article-title":"Is there a risk of esketamine misuse in clinical practice?","volume":"16","author":"Roncero","year":"2025","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.jad.2026.122106_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.12616","article-title":"Transcranial magnetic stimulation and transcranial direct current stimulation across mental disorders: a systematic review and dose-response meta-analysis","volume":"7","author":"Sabe","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2026.122106_bb0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41398-021-01372-0","article-title":"Association of co-occurring opioid or other substance use disorders with increased healthcare utilization in patients with depression","volume":"11","author":"Vekaria","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.122106_bb0175","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/s43440-025-00730-9","article-title":"Non-response to short-term ketamine use for treatment-resistant depression","volume":"77","author":"Walaszek","year":"2025","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jad.2026.122106_bb0180","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jad.2022.01.047","article-title":"Safety of transcranial magnetic stimulation in unipolar depression: a systematic review and meta-analysis of randomized-controlled trials","volume":"301","author":"Wang","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122106_bb0185","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726009584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:59:32Z","timestamp":1784577572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726009584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S0165032726009584"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122106","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122106"}}